Embelin Elevates Endoplasmic Reticulum Calcium Levels and Blocks the Sterol Regulatory Element-Binding Protein 2 Mediated Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Improves the Low-Density Lipoprotein Receptor Mediated Lipid Clearance on Hepatocytes

被引:0
|
作者
Chandran, Mahesh [1 ,2 ,3 ]
Rameshkumar, K. B. [4 ]
Jaleel, Abdul [3 ]
Ayyappan, Janeesh Plakkal [1 ,2 ,5 ]
机构
[1] Univ Kerala, Dept Biochem, Translat Nanomed & Lifestyle Dis Res Lab, Thiruvananthapuram, Kerala, India
[2] Univ Kerala, Dept Biotechnol, Thiruvananthapuram, Kerala, India
[3] Rajiv Gandhi Ctr Biotechnol, DBT SAHAJ Natl Facil Mass Spectrometry, Thiruvananthapuram, Kerala, India
[4] Jawaharlal Nehru Trop Bot Garden & Res Inst Palode, Thiruvananthapuram, Kerala, India
[5] Univ Kerala, Ctr Adv Canc Res, Dept Biochem, Thiruvananthapuram, Kerala, India
关键词
atherosclerosis; embelin; hypercholesterolemia; PCSK9; SREBP2; ER STRESS; MYOCARDIAL INJURY; ACTIVATION; DYSFUNCTION; METABOLISM;
D O I
10.1111/cbdd.70055
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cardiovascular diseases (CVDs) continue to be one of the leading causes of morbidity and mortality worldwide, with a significant increase in recent years. Atherosclerosis, the pathological basis and prime reason for CVDs is primarily driven by dysregulated lipid metabolism and inflammation. Recently, proprotein convertase subtilisin kexin9 (PCSK9) has been evolved to be highly implicated in the circulatory low-density lipoprotein cholesterol levels by its modulatory effects on the low-density lipoprotein receptor (LDLR) mediated clearance. Even though not economical, the therapies targeting PCSK9 demonstrated appreciable levels of efficiency in managing hyperlipidaemic conditions. Embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone) is a naturally occurring para-benzoquinone isolated from dried berries of Embelia ribes, which possess several effects in maintaining the cholesterol homeostasis. In this study, we have analysed the role of embelin in sterol regulatory element-binding protein 2 (SREBP2) mediated PCSK9 expression in cultured hepatocytes. The study showed that the embelin treatment attenuates the endoplasmic reticulum (ER) stress-induced reactive oxygen species levels and ER stress markers on cultured hepatocytes. The treatment of embelin modulates the mRNA and protein level expression of SREBP2 and its downstream targets like PCSK9, LDLR, and HMG-CoA reductase (HMGCR). Interestingly the Ca2+ levels and the calcium binding protein of ER were significantly increased with embelin treatment. The work revealed a putative mechanism of embelin in lowering PCSK9 levels by boosting ER Ca2+ levels, thereby blocking SREBP2 nuclear translocation. Further, this reduces LDLR degradation and increases receptor-mediated circulatory lipid clearance. The study summarized the potential clinical applications of embelin in addressing the cardio vascular diseases.
引用
收藏
页数:12
相关论文
共 17 条
  • [1] Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2
    Jeong, Hyun Jeong
    Lee, Hyun-Sook
    Kim, Kyung-Sup
    Kim, Yoon-Kyoung
    Yoon, Dojun
    Park, Sahng Wook
    JOURNAL OF LIPID RESEARCH, 2008, 49 (02) : 399 - 409
  • [2] Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways
    Cameron, Jamie
    Bogsrud, Martin P.
    Tveten, Kristian
    Strom, Thea Bismo
    Holven, Kirsten
    Berge, Knut Erik
    Leren, Trond P.
    TRANSLATIONAL RESEARCH, 2012, 160 (02) : 125 - 130
  • [3] Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein Receptor Suppression Mediated in Part by Proprotein Convertase Subtilisin/Kexin Type 9
    Melone, Michelle
    Wilsie, Larissa
    Palyha, Oksana
    Strack, Alison
    Rashid, Shirya
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (19) : 1697 - 1705
  • [4] Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin tyoe-9 and is required for the degration of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
    Jang, Hyun-Duk
    Lee, Sang Eun
    Yang, Jimin
    Lee, Hyun-Chae
    Shin, Dasom
    Lee, Hwan
    Lee, Jaewon
    Jin, Sooryeonhwa
    Kim, Soungchan
    Lee, Seung Ji
    You, Jihye
    Park, Hyun-Woo
    Nam, Ky-Youb
    Lee, Sang-Hak
    Park, Sahng Wook
    Kim, Jin-Soo
    Kim, Sang-Yeob
    Kwon, Yoo-Wook
    Kwak, Soo Heon
    Yang, Han-Mo
    Kim, Hyo-Soo
    EUROPEAN HEART JOURNAL, 2020, 41 (02) : 239 - +
  • [5] Lipoprotein(a) Internalization in HepG2 Cells is Regulated by Proprotein Convertase Subtilisin Kexin Type 9 Through the Low-Density Lipoprotein Receptor
    Romagnuolo, Rocco
    Seidah, Nabil G.
    Koschinsky, Marlys L.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34
  • [6] Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells
    Mousavi, Seyed A.
    Berge, Knut E.
    Berg, Trond
    Leren, Trond P.
    FEBS JOURNAL, 2011, 278 (16) : 2938 - 2950
  • [7] Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
    Kosenko, Tanja
    Golder, Mia
    Leblond, Geoffrey
    Weng, Willy
    Lagace, Thomas A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (12) : 8279 - 8288
  • [8] Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies
    Rey, Jacques
    Poitiers, Franck
    Paehler, Tobias
    Brunet, Aurelie
    DiCioccio, A. Thomas
    Cannon, Christopher P.
    Surks, Howard K.
    Pinquier, Jean-Louis
    Hanotin, Corinne
    Sasiela, William J.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (06):
  • [9] Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children
    Girona, Josefa
    Rodriguez-Borjabad, Celia
    Ibarretxe, Daiana
    Heras, Mercedes
    Amigo, Nuria
    Feliu, Albert
    Masana, Luis
    Plana, Nuria
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (01) : 211 - 218
  • [10] From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients
    Zenti, Maria G.
    Altomari, Anna
    Lupo, Maria G.
    Botta, Margherita
    Bonora, Enzo
    Corsini, Alberto
    Ruscica, Massimiliano
    Ferri, Nicola
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2018, 25 (17) : 1843 - 1851